Uncategorized

GSK CEO’s ‘scientific courage’ propels plans for medley of phase 3 trials for Hansoh-partnered ADC

Published

5 days ago

on

When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of antibody-drug conjugates (ADCs).

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version